Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.

Details

Ressource 1Download: serval:BIB_5F515113D09B.P001 (131.55 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_5F515113D09B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.
Journal
Journal of Antimicrobial Chemotherapy
Author(s)
Vouillamoz J., Moreillon P., Giddey M., Entenza J.M.
ISSN
0305-7453[print], 0305-7453[linking]
Publication state
Published
Issued date
2006
Volume
58
Number
6
Pages
1208-1214
Language
english
Abstract
OBJECTIVES: Daptomycin was tested in vitro and in rats with experimental endocarditis against the ampicillin-susceptible and vancomycin-susceptible Enterococcus faecalis JH2-2, the vancomycin-resistant (VanA type) mutant of strain JH2-2 (strain JH2-2/pIP819), and the ampicillin-resistant and vancomycin-resistant (VanB type) Enterococcus faecium D366. METHODS: Rats with catheter-induced aortic vegetations were treated with doses simulating intravenously kinetics in humans of daptomycin (6 mg/kg every 24 h), amoxicillin (2 g every 6 h), vancomycin (1 g every 12 h) or teicoplanin (12 mg/kg every 12 h). Treatment was started 16 h post-inoculation and continued for 2 days. RESULTS: MICs of daptomycin were 1, 1 and 2 mg/L, respectively, for strains JH2-2, JH2-2/pIP819 and D366. In time-kill studies, daptomycin showed rapid (within 2 h) bactericidal activity against all strains. Daptomycin was highly bound to rat serum proteins (89%). In the presence of 50% rat serum, simulating free concentrations, daptomycin killing was maintained but delayed (6-24 h). In vivo, daptomycin treatment resulted in 10 of 12 (83%), 9 of 11 (82%) and 11 of 12 (91%) culture-negative vegetations in rats infected with strains JH2-2, JH2-2/pIP819 and D366, respectively (P < 0.001 compared to controls). Daptomycin efficacy was comparable to that of amoxicillin and vancomycin for susceptible isolates. Daptomycin, however, was significantly (P < 0.05) more effective than teicoplanin against the glycopeptide-susceptible strain JH2-2 and superior to all comparators against resistant isolates. CONCLUSIONS: These results support the use of the newly proposed daptomycin dose of 6 mg/kg every 24 h for treatment of enterococcal infections in humans.
Keywords
Amoxicillin/administration & dosage, Amoxicillin/blood, Animals, Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/blood, Blood Proteins/metabolism, Daptomycin/administration & dosage, Daptomycin/blood, Disease Models, Animal, Drug Resistance, Multiple, Bacterial, Endocarditis, Bacterial/drug therapy, Endocarditis, Bacterial/microbiology, Enterococcus faecalis/drug effects, Enterococcus faecium/drug effects, Female, Microbial Sensitivity Tests, Microbial Viability, Protein Binding, Rats, Rats, Wistar, Teicoplanin/administration & dosage, Teicoplanin/blood, Vancomycin/administration & dosage, Vancomycin/blood
Pubmed
Web of science
Open Access
Yes
Create date
24/01/2008 14:45
Last modification date
25/09/2019 7:09
Usage data